DISCOVER ANTIBODIES WIDER, DEEPER & FASTER
WITH AbTHENEUM™
An innovative approach to isolate sought-after antibodies
for precision medicine applications by direct interrogation of immune cells
CONTACT US
Unrivaled Immune Response Analysis for Your Next Target

Thousands Of
Antibodies
Thousands Of
Antibodies
SCT discovers thousands of antigen specific antibodies, clusters them into putative epitope groups, and provides binding data paired to full sequences

Massive
Informatics
Massive
Informatics
Our bioinformatic experts and proprietary algorithms find the best antibody candidates from thousands of sequences to streamline downstream processing

An Entirely New
Approach
An Entirely New
Approach
By combining molecular biology with Silicon Valley developed wafer and optical technologies, we’ve reinvented the way antibodies are discovered

Intellectual
Property
Intellectual
Property
SCT has broad and fundamental patents on associating antibody sequences with their phenotype in a massively parallel and scalable process

Perfect
Partner
Perfect
Partner
SCT decreases time-to-market and increases success of your next antibody campaign
Single Cell Technology® (SCT) independently developed a new generation of antibody discovery platform AbTheneum™. Intellectual property rights (currently 11 issued patents) are exclusively owned in the U.S.A., Canada, the European Union, Japan, South Korea, India, and Australia.
VIEW SCIENCE AND TECHLatest News

We are not
- Another hybridoma or phage display company
- Spreading cells on a surface, e.g.: SLAM (Selected Lymphocyte Antibody Method)
- Sorting cells, depositing single cells in a tray, and performing RT-PCR
- Using a micromanipulator to pull out potentially interesting cells